AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB
Treatment and conditionWhere it standsTrials
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1